FS KKR Capital Corp. (FSK) Q1 2026 earnings review
Credit Deterioration Triggers Emergency KKR Lifeline
The bottom is falling out of FSK's credit portfolio. Net Asset Value (NAV) collapsed by nearly 10% sequentially to $18.83 per share, driven by a massive $2.00 per share realized and unrealized loss. Defaulting loans (non-accruals) have surged to 8.1% of cost, forcing leverage up to 131%—well above management's historical target range. The situation is severe enough that KKR has intervened with a four-part emergency rescue package: a $150M preferred equity injection, a 50% waiver of its incentive fees, a $150M tender offer, and a $300M share repurchase program. Earnings are decelerating sharply, with Net Investment Income (NII) dropping to $0.42, prompting a subsequent cut to the Q2 distribution to match.
🐂 Bull Case
The $150M preferred equity injection and the 50% waiver on subordinated incentive fees prove that the KKR parent is willing to absorb pain to stabilize the BDC. The fee waiver directly supports NII and the distribution level.
The combined $150M tender offer and $300M share repurchase program will be highly accretive to NAV if executed at current market prices, creating a mechanical floor for the stock.
🐻 Bear Case
Non-accruals accelerating to 8.1% at cost is deeply alarming. Prior quarters revealed structural issues in healthcare rollups and software; this quarter proves the rot is deeper than previously admitted.
Net debt to equity exploded to 131%. The company had to amend its credit facility, taking a penalty on margins and reducing total commitments to avoid a covenant crisis.
⚖️ Verdict: 🔴🔴
Bearish. While KKR's intervention prevents a total freefall, the underlying portfolio is severely impaired. A BDC running at 131% leverage with 8.1% of its book effectively broken leaves zero margin for error.
Key Themes
Non-Accrual Avalanche
Accelerating. The volume of defaulting loans is staggering. Investments on non-accrual status leaped to 8.1% of amortized cost (4.2% of fair value), up from 5.5% (3.4% FV) just one quarter ago. For context, in Q1 2025, non-accruals were at a manageable 3.5%. This rapid deterioration indicates that the aggressive workouts and restructurings touted by management throughout 2025 have failed to stem the bleeding in legacy legacy investments.
Leverage Target Breached
Accelerating. Net debt to equity surged to 131%, shattering the company's historical target range of 100% to 125%. This isn't because they are borrowing to fund aggressive growth—total purchases were a measly $499M—it's because the equity base is evaporating due to writedowns. This forced FSK to amend its revolving credit facility, suffering an increase in borrowing margins (up to 1.9%) and reducing total facility commitments by over $600M.
KKR's Four-Part Rescue Package
To stop the bleeding, KKR is orchestrating a massive intervention. First, injecting $150M via a Convertible Perpetual Preferred stock (yielding 5% cash or 7% PIK). Second, launching a $150M tender offer for common shares at $11.00. Third, authorizing a standard $300M open-market buyback. Fourth, waiving 50% of the subordinated income incentive fee for four quarters. This creates a mechanical backstop to earnings and provides desperately needed equity cushion.
Tender Price Contradicts Valuation Confidence
Management's official statement claims 'KKR believes the intrinsic value of FSK's common stock is in excess of the Tender price of $11.00 per share.' However, offering to buy shares at $11.00 when the stated NAV is $18.83 represents a massive 41% discount. This directly contradicts the positive narrative around their mark-to-market accounting. If management truly believed the $18.83 NAV was solid, tendering at $11.00 signals they are either capitalizing on retail panic, or quietly acknowledging the legacy book holds further undisclosed impairments.
Macro Headwinds: Spread Widening
CEO Michael Forman explicitly cited 'the impact of market-driven spread widening in certain segments of our portfolio' as a primary driver of the NAV decline. As the broader macroeconomic environment forces a re-pricing of credit risk, FSK's heavily levered portfolio is taking a mark-to-market beating. The weighted average annual yield on all debt investments plummeted from 9.3% in Q4 to 8.7% in Q1.
Pivoting Toward Asset-Based Finance
Stable. As traditional corporate software and healthcare roll-up credits blow up, FSK continues to lean on its Asset-Based Finance (ABF) allocation. ABF structures, which are anchored to hard collateral rather than volatile corporate cash flows, maintained a steady 13.5% of total portfolio fair value (up slightly from 13.0%). This specific structural product innovation remains one of the few reliable defensive anchors in the book.
Other KPIs
Decelerating. NII fell from $0.48 in Q4 2025 and $0.67 in Q1 2025. This 37% YoY collapse in core earnings power reflects the dual drag of elevated non-accruals (loans no longer paying interest) and lower yields across the accruing portfolio. The newly declared Q2 distribution of $0.42 simply matches this lowered run-rate.
Accelerating. This translates to an eye-watering $2.00 per share loss for a single quarter, more than double the $0.89 per share loss recorded in Q4. It completely wiped out the quarter's $117M in net investment income, fundamentally driving the massive book value destruction.
Guidance
Decelerating. FSK continues to slash its payout to match its crumbling earnings reality. For context, FSK was paying out $0.70 per quarter in early 2025. The new $0.42 base represents a 40% absolute reduction in income for shareholders from peak levels.
Starting in Q2 2026, KKR will waive 50% of the subordinated income incentive fee. In Q1, this fee was $25M. Slicing this in half will artificially inflate NII by roughly $0.04 to $0.05 per share per quarter, essentially subsidizing the newly lowered $0.42 dividend.
Key Questions
True Floor for Non-Accruals
With non-accruals surging from 5.5% to 8.1% of cost in a single quarter, what is the internal forecast for peak defaults? Are there more major legacy restructurings (similar to PRG or DCA) waiting in the pipeline?
Leverage Restraints on Origination
Operating at 131% net leverage limits your capacity to originate out of this problem. During the $300M share repurchase period, how severely will new investment originations be choked off to fund buybacks and pay down the revolver?
The $11 Tender Offer Logic
If management genuinely believes the NAV is $18.83, why set the tender offer at a punitive $11.00 per share? Doesn't this signal to the market that the internal base-case valuation for the portfolio is actually much closer to $11 than $18?